ATGAM associated coagulopathy in renal transplant patients: a report of two unusual cases.
Polyclonal antibodies, used for both induction and rejection therapy in renal transplant recipients, are associated with such side effects as chills and fever. We describe two patients who developed a coagulopathy during antithymocyte globulin (ATGAM) therapy, a previously unknown complication. The laboratory tests revealed prolonged prothrombin and partial thromboplastin times and thrombocytopenia. Discontinuation of ATGAM therapy resulted in correction of these abnormalities.
Trivedi
H S
HS
Department of Internal Medicine, University of Missouri, Columbia, USA.
Lal
S M
SM
Gupta
N
N
Ross
G
G
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D010314:Partial Thromboplastin Time; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011183:Postoperative Complications; D011516:Prothrombin / Q000032:analysis; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced; D044465:White People
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011516:Prothrombin